Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

对泰国高疾病活动度类风湿关节炎患者，采用生物制剂类疾病修饰抗风湿药（bDMARDs）、靶向合成DMARDs（tsDMARDs）和生物类似药DMARDs（bsDMARDs）联合甲氨蝶呤治疗的成本效益分析